Navigation Links
Januvia Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Order Transferring Federal Claims Over Januvia and Pancreatic Cancer to California Federal Court
Date:8/27/2013

New York, New York (PRWEB) August 27, 2013

Januvia lawsuits continue to move forward, (http://www.thejanuvialawsuit.com/ ) following a decision by the U.S. Judicial Panel on Multidistrict Litigation to transfer all federally-filed product liability claims involving Januvia and similar diabetes drugs to a single federal court for pretrial proceedings, Bernstein Liebhard LLP reports. According to a Transfer Order dated August 26, 2013, the newly-formed multidistrict litigation will be presided over by the Honorable Anthony J. Battaglia in the U.S. District Court, Southern District of California. All of the Januvia lawsuits transferred to the proceeding accuse Merck & Co. of failing to provide doctors and patients with adequate warnings regarding a potential link between Januvia and pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

“Our Firm has received numerous Januvia lawsuit inquiries from individuals who were diagnosed with pancreatic cancer while using this diabetes drug. The multidistrict litigation established in California federal court will provide an efficient means for resolving what could be a large number of claims,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal evaluations to alleged victims of Januvia pancreatic cancer, as well as pancreatitis and thyroid cancer.

Januvia and Pancreatic Cancer
Court documents indicate that 53 product liability claims, including Januvia lawsuits, have been filed in various federal courts on behalf of patients who allege their use of type 2 diabetes medications known as incretin mimetics resulted in the development of pancreatic cancer. A multidistrict litigation, such as the one established for these claims, consolidates all lawsuits involving common questions of fact in one jurisdiction for coordinated pretrial proceedings. The aim of a multidistrict litigation is to avoid duplicative discovery and inconsistent rulings across similar lawsuits, and to conserve the resources of the court, parties and witnesses.

In recent years, incretin mimetics like Januvia have been the subject of growing concerns surrounding their potential to harm the pancreas. In 2009, a caution regarding a link between Januvia and pancreatitis – a risk factor for pancreatic cancer - was added to the drug’s label after the U.S. Food & Drug Administration (FDA) became aware of 88 instances where Januvia patients had developed acute pancreatitis.* In 2011, a study published in Gastroenterology found that use of Januvia appeared to increase the risk of pancreatitis and pancreatic cancer, while two cases of thyroid cancer were also reported in the patients who took Januvia.**

In March of this year, the FDA announced that it was investigating incretin mimetics after results from an unpublished study indicated these medications might cause pre-cancerous changes in the pancreas. While the agency has not yet been able to confirm a conclusive link between the use of such drugs and pancreatic cancer, it has said its “review is ongoing as pancreatitis and pancreatic cancer data are being collected.”*** Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.****

Patients who have developed pancreatic cancer, thyroid cancer or pancreatitis that may be related to the use of Januvia could be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn More about the possible link between Januvia and pancreatic cancer by visiting Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/ucm343187.htm
**http://www.gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
***pharmalive.com/fda-decides-no-risk-of-pancreatic-cancer-with-diabetes-drugs, Pharmalot, July 31, 2013
****bmj.com/open-data/incretin#alternate; BMJ, June 10, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thejanuvialawsuit.com/

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb11065983.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Announces Addition of Januvia Cancer Resource Center
2. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
3. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
4. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
5. Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
6. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
7. Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
8. Januvia Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on Medical Journal’s Investigation of Incretin Mimetics
9. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
10. New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
11. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: